Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Ovarian Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Non Small Cell Lung Carcinoma NSCLC 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Triple Negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Non-Small Cell Lung Cancer With HER2- Mutations 1Neoplasms, Unknown Primary 1Neoplasms 1NSCLC 1Head and Neck Neoplasms 1First-line Advanced NSCLC Patients 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Ovarian Epithelial 1Carcinoma 1

Interventions

Paclitaxel 32Carboplatin 23liposomal doxorubicin 14pembrolizumab 12Topotecan 10Bevacizumab 10Gemcitabine 9mirvetuximab soravtansine 8olaparib 6Cisplatin 61-dodecylpyridoxal 6rucaparib 5Nivolumab 5Cyclophosphamide 5oregovomab 4farletuzumab 3catumaxomab 3Standard of Care 3Irinotecan 3Fulvestrant 3CCV-AV protocol 3talazoparib 2sacituzumab govitecan 2ribociclib 2phenoxodiol 2pegfilgrastim 2pazopanib 2palbociclib 2niraparib 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Ovarian Epithelial × CP protocol × Clear all
NCT02855944 2023-06-09

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

pharmaand GmbH

Phase 3 Completed
349 enrolled 29 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡